North America Osteoporosis Drugs Market By Route of Administration (Oral, Injectable and Other Route of Administration) By Drug Class (Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes) By Country, Industry Analysis and Forecast, 2020 - 2026

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Osteoporosis Drugs Market, by Route of Administration
1.4.2 North America Osteoporosis Drugs Market, by Drug Class
1.4.3 North America Osteoporosis Drugs Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. North America Osteoporosis Drugs Market by Route of Administration
3.1 North America Oral Market by Country
3.2 North America Injectable Market by Country
3.3 North America Other Route of Administration Market by Country

Chapter 4. North America Osteoporosis Drugs Market by Drug Class
4.1 North America Bisphosphonates Market by Country
4.2 North America Rank Ligand Inhibitors Market by Country
4.3 North America Parathyroid Hormone Therapy Market by Country
4.4 North America Calcitonin Market by Country
4.5 North America Other Drug Class Market by Country

Chapter 5. North America Osteoporosis Drugs Market by Country
5.1 US Osteoporosis Drugs Market
5.1.1 US Osteoporosis Drugs Market by Route of Administration
5.1.2 US Osteoporosis Drugs Market by Drug Class
5.2 Canada Osteoporosis Drugs Market
5.2.1 Canada Osteoporosis Drugs Market by Route of Administration
5.2.2 Canada Osteoporosis Drugs Market by Drug Class
5.3 Mexico Osteoporosis Drugs Market
5.3.1 Mexico Osteoporosis Drugs Market by Route of Administration
5.3.2 Mexico Osteoporosis Drugs Market by Drug Class
5.4 Rest of North America Osteoporosis Drugs Market
5.4.1 Rest of North America Osteoporosis Drugs Market by Route of Administration
5.4.2 Rest of North America Osteoporosis Drugs Market by Drug Class

Chapter 6. Company Profiles
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.1.4 Recent strategies and developments:
6.1.4.1 Partnerships, Collaborations, and Agreements:
6.1.4.2 Approvals:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 GlaxoSmithKline PLC (GSK)
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.4 Merck & Co., Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expenses
6.5 Novartis AG
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Recent strategies and developments:
6.5.4.1 Partnerships, Collaborations, and Agreements:
6.6 Pfizer, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Sun Pharmaceutical Industries Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Teva Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expenses
6.9 Allergan PLC
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.1 Eli Lilly and Company
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expense